

EXOMIND: Symptoms of Depression

ExoTMS™ Technology: A Novel Breakthrough in Transcranial Magnetic Stimulation for Enhancing Mental Well-Being

Michelle Dees MD¹, Yael Halaas MD², JD McCoy NMD³

1. Luxury Psychiatry Clinic, Winter Garden, FL, USA, 2. Science & Beauty Associates, New York, NY, USA, , 3. Contour Medical, Gilbert, AZ, USA

Published in the Journal of Psychiatry and Psychiatric Disorders

DOI: 10.26502/jppd.2572-519X0255

Highlights

- 33 patients (25-78 years, BMI 17.5-43.1 kg/m²) seeking improvement in their mental well-being were enrolled in an IRB approved trial
- Out of these, 12 patients (27–58 years, BMI 17.5–43.1 kg/m²) had a psychiatric diagnosis of depression
- Patients received 4 Exomind treatments spaced 3-7 days apart
- Patients were evaluated using the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS), Subject Satisfaction Questionnaire (SSQ), and Therapy Comfort Questionnaire (TCQ)
- 100% of patients found the therapies comfortable; no serious adverse events were reported

83%

Patients reported feeling less depressed and less stressed (SSQ) at 3-month follow-up

82%

Patients reported improved mood (SSQ) at 3-month follow-up

83%

Patients showed improved mental well-being scores (WEMWBS) at 3-month follow-up




Figure 1: Patients improved their WEMWBS scores from baseline to the last treatment and maintained the improvement at the 3-month follow-up.